Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function.

Rituvanthikaa SeethapathyQiyu WangSophia ZhaoIan A StrohbehnJoshua D LongJames E DinulosDestiny HardenVinay B KadiyalaDaiana MorenoMeghan E Sise

Published in: PloS one (2023)

Remdesivir use in patients with impaired kidney function (eGFR between 15 - 60 mL/min/1.73m2) who present to the hospital with COVID-19 is not associated with increased risk of adverse kidney outcomes.

Keyphrases

coronavirus disease
small cell lung cancer
sars cov
adverse drug
healthcare
epidermal growth factor receptor
tyrosine kinase
type diabetes
emergency department
metabolic syndrome
glycemic control